cancer treatments and rheumatologic disease Archives

Abstract Number: 2119 • ACR/ARHP Annual Meeting 2017
Rheumatological Immune Related Adverse Events in Malignancy Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies
Emma Mitchell¹, Peter Lau², Chloe Khoo², Kortnye Smith², Benjamin Brady², Mark Shackleton², Grant McArthur², Ian Wicks^1,3,4 and Shahneen Sandhu², ¹Rheumatology, Royal Melbourne Hospital, Melbourne, Australia, ²Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia, ³Medicine, University of Melbourne, Melbourne, Australia, ⁴Wicks Lab, Walter and Eliza Hall Institute, Melbourne, Australia
Background/Purpose: Immune checkpoint inhibitors (ICIs), including anti-programmed cell death 1 (anti-PD 1) antibodies, are established therapies for advanced malignancies, including melanoma, and non-small cell lung…

Abstracts tagged "cancer treatments and rheumatologic disease"